Bladder cancer and urinary microbiota in adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

In France, bladder cancer is a common cancer that mainly affects older men, with smoking as a major risk factor. Researchers will examine bladder tissue samples from adults undergoing diagnostic procedures to explore how urinary microbiota may be linked to bladder cancer. The study uses a biopsy-based approach to collect tissue for microbiota analysis. It is an observational/interventional design focusing on the association between microbiota and bladder cancer characteristics. Eligible participants are adults with suspected bladder cancer who give informed consent and are not recently treated with antibiotics or undergoing active infections at enrollment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age \> 18 years old
* Male
* First RTUV for suspected CV in the presence of macroscopic haematuria or other clinical signs and/or urinary cytology and/or cystoscopy and/or imaging tests suggestive of CV
* Signed informed consent form
* Affiliation with a social security scheme

Exclusion Criteria:

* Antibiotic use within 3 months prior to inclusion
* Current urinary tract infection (urine culture recommended by the AFU prior to RTUV)
* History of surgical treatment of the urinary and genital tracts within the last 6 months prior to inclusion
* History of RTUV
* History of pelvic radiotherapy
* Interstitial cystitis
* Patients with an indwelling urinary catheter
* Vulnerable patients: minors, patients under guardianship or curatorship
* Patients with benign tumours after receipt of the pathological report (inverted papilloma, non-tumour inflammatory lesion)

Where it's running

• Nice University Hospital
  Nice, France Recruiting
• Cannes Hospital
  Cannes, France Not yet recruiting
• Marseille university Hospital
  Marseille, France Not yet recruiting
• Menton Hospital
  Menton, France Not yet recruiting
• Nimes University hospital
  Nîmes, France Not yet recruiting
• Paris University Hospital
  Paris, France Not yet recruiting

Study contacts

• Study coordinator: Alice GAUDART
• Email: gaudart.a@chu-nice.fr
• Phone: 04 92 03 62 14

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• BL-M07D1: T-bren vs standard platinum chemo for HER2-expressing metastatic urothelial cancer after anti-PD-(L)1 therapy

  This trial tests whether T-bren can help people with HER2-expressing metastatic urothelial cancer who progressed after anti-PD-(L)1 therapy, compared with standard platinum-based chemotherapy.

  Recruiting at 2 sites Phase 3 SystImmune Inc. · Macon, Georgia and 1 other locations · NCT07869836

• Intravesical UGN-501 for Recurrent NMIBC (Phase 1, dose-escalation)

  This study tests whether UGN-501 can be safely given into the bladder to treat adults with recurrent non-muscle invasive bladder cancer.

  Recruiting at 6 sites Phase 1 UroGen Pharma Ltd. · Queen Creek, Arizona and 14 other locations · NCT07725796

• Is ongoing systemic immunotherapy needed after achieving tumor-free status in very-high-risk NMIBC?

  This study tests whether patients who have become tumor-free after a systemic immunotherapy-based bladder-sparing treatment can safely stop therapy and instead be watched closely.

  Recruiting at 4 sites Phase 2 Tianjin Medical University Second Hospital · Tianjin and 3 other locations · NCT07625527

• Irrigation Fluid Absorption and Perioperative cfDNA Changes in TURBT for Bladder Cancer

  This study tests whether the amount of irrigation fluid absorbed during TURBT is linked to changes in tumor DNA circulating in the blood in patients with bladder cancer.

  Recruiting Lanzhou University Second Hospital · Lanzhou, Gansu · NCT07589413

• TARA-002 vs chemotherapy for high-grade non-muscle invasive bladder cancer in adults not previously treated with BCG

  A phase 3 study tests whether TARA-002 can help adults with high-grade non-muscle invasive bladder cancer who haven’t had BCG, comparing it to standard intravesical chemotherapy.

  Recruiting at 11 sites Phase 3 Protara Therapeutics · Queen Creek, Arizona and 10 other locations · NCT07480356

• Liquid biopsy testing to identify, monitor, and predict recurrence in urothelial carcinoma

  This project tests whether a multi-component liquid biopsy (blood and urine ctDNA, urine tumor DNA, exosomes, and protein biomarkers) can help detect disease, track treatment response, and predict recurrence in people with suspected or confirmed urothelial carcinoma.

  Recruiting Tianjin Medical University Second Hospital · Tianjin · NCT07441499

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.